Equazen® Reaffirms Its Commitment to Uncompromising Quality and Sustainability in Omegas Supplements
SFI Health™ EMEA, the regional entity of SFI Health™, a global leader in natural healthcare, highlights today its ongoing commitment to delivering the highest standard of quality for Equazen ®, the company's global science-based food supplement brand designed to nourish, enhance and support the brain's potential.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250625554235/en/
Equazen® continues to set the benchmark for excellence at every step of the value chain
At SFI Health™, quality is more than a requirement—it is a mission. The company is committed to enhancing people's well-being by developing natural supplements that combine passion for nature-based healthcare, science, state-of-the-art production standards and sustainability, from ingredient sourcing to the final product reaching the patient.
In particular, with over 25 years of trust built across multiple markets, Equazen ® 's excellence is built on five core pillars:
'Our mission with Equazen ® is to provide natural supplements that parents and caregivers can trust to support cognitive needs and the health of human brain,' said Matthew Brabazon, General Manager at SFI Health™ EMEA. 'This is made possible only through ethical sourcing, advanced manufacturing, and robust scientific validation.'
As market demands evolve, Equazen ® remains dedicated to pushing quality standards further at every step of the value chain to offer best-in-class solutions for optimal cognitive health. Consumers can trust that every product reflects a passion for health, innovation, and sustainability.
About SFI Health™
SFI Health™ is a global leader in natural healthcare, specialized in the design, development and commercialization of clinically researched products in the areas of microbiome, cognition and wellbeing.
Guided by the belief in the healing potential of natural products, SFI Health™ combines a rigorous pharma-based approach with the benefits of naturally sourced solutions.
An extensive network of trusted business partners enables the company, headquartered in Australia, to market its own brands, reaching consumers in over 50 countries. The EMEA SFI Health™ regional office in Lugano, Switzerland, manages commercial operations across Europe, Middle East and Africa.
SFI Health™ is committed to fostering confidence in natural healthcare by sharing state-of-the-art research, technical expertise and comprehensive sales & marketing resources with consumers, healthcare professionals and partners worldwide.
For more information, go to sfihealth.com or follow us SFI Health on LinkedIn.
About Equazen®
Equazen ® is a science-based globally branded food supplement designed and studied to help nourish, enhance, and support the human brain's potential across all life stages.
Each product of the Equazen ® range contains a balanced unique combination of essential fatty acids (Omega-3 and Omega-6), which has been clinically proven for more than 20 years to assist with learning capabilities, concentration and healthy brain development.
Equazen ® is available in multiple pharmaceutical formats and sizes to support optimal cognitive functions from infants to teenagers.
Currently marketed in 30 countries globally, Equazen ® is widely recommended by healthcare professionals and trusted by families for the last 25 years.
Equazen ® aims to advance human health naturally, delivering expertly formulated products that empower individuals to reach their cognitive potential.
For more info visit www.equazen.com
View source version on businesswire.com:https://www.businesswire.com/news/home/20250625554235/en/
CONTACT: For more information
SFI Health™ EMEA Contact
Elisabetta Bianchi
e-mail address:[email protected]
KEYWORD: SWITZERLAND EUROPE
INDUSTRY KEYWORD: HEALTH ENVIRONMENT SUSTAINABILITY FITNESS & NUTRITION GENERAL HEALTH VITAMINS/SUPPLEMENTS
SOURCE: SFI Health
Copyright Business Wire 2025.
PUB: 06/26/2025 02:00 AM/DISC: 06/26/2025 01:59 AM
http://www.businesswire.com/news/home/20250625554235/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 hours ago
- Yahoo
Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 14, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an exclusive license agreement with Venatorx Pharmaceuticals, Inc., to acquire the global rights to ceftibuten-ledaborbactam etzadroxil, a clinical phase 3-ready oral beta-lactam/beta-lactamase inhibitor (BL/BLI) combination for the potential treatment of complicated urinary tract infections (cUTI), including pyelonephritis. Ceftibuten-ledaborbactam etzadroxil is the combination of ceftibuten, an orally bioavailable cephalosporin antibiotic, and ledaborbactam etzadroxil, the orally bioavailable prodrug of the novel beta-lactamase inhibitor ledaborbactam. The combination demonstrates bactericidal activity against Enterobacterales, including multidrug-resistant pathogens, the major cause of cUTI.[1] In the USA, cUTI account for more than 600,000 hospital admissions each year.[2] This underscores the significant clinical burden and need for effective oral treatment options, which may shorten or entirely avoid hospitalization. In preclinical and clinical phase 1 studies, ceftibuten and ledaborbactam etzadroxil were shown to be safe and well tolerated.[3] David Veitch, Chief Executive Officer of Basilea, said: 'This agreement allows us to strengthen our late-stage clinical pipeline and supports our strategy of ensuring that we have a continuous stream of potential new product launches in the near-term future, positioning us for sustainable substantial revenue growth. Ceftibuten-ledaborbactam etzadroxil holds strong promise in addressing the critical unmet need for the oral treatment of cUTI caused by multidrug-resistant Gram-negative bacteria and represents a compelling global commercial opportunity. We expect starting a registrational phase 3 program in cUTI in about 18 months.' Under the terms of the agreement, Basilea will make an upfront payment and potential milestone payments in 2025. Following the successful completion of the phase 3 clinical development program and after the grant of regulatory approval and start of commercialization, Venatorx is eligible to receive tiered mid-single-digit royalties and additional potential milestone payments of up to USD 325 million in total, if all agreed commercial milestone events are triggered over the term of the contract. The transaction is expected to result in approximately CHF 15 million of additional research and development expenses in 2025, including the full upfront payment, all potential pre-commercial milestone payments and expected R&D expenses in 2025. Basilea will provide updated financial guidance for the full-year 2025, reflecting this transaction, with the half-year earnings report on August 19, 2025. About beta-lactam/beta-lactamase inhibitor (BL/BLI) combinations Many Gram-negative bacteria express enzymes such as extended spectrum beta-lactamases (ESBL) that confer resistance against commonly used antibiotics. Beta-lactamase inhibitors block these enzymes and restore the activity of beta-lactam antibiotics against initially resistant Gram-negative bacteria, therefore BL/BLI combinations are an important addition to the armamentarium for the treatment of infections by multidrug-resistant bacterial pathogens. About ceftibuten-ledaborbactam etzadroxil Ledaborbactam etzadroxil is the orally bioavailable prodrug of ledaborbactam, a novel broad-spectrum boronic acid beta-lactamase inhibitor, which is being developed in combination with ceftibuten, an oral cephalosporin antibiotic, which is approved in the US for the treatment of upper and lower respiratory tract infections and for urinary tract infections outside the US. In vitro and in vivo studies demonstrated that ledaborbactam etzadroxil restores the activity of ceftibuten against strains of Enterobacterales expressing Ambler class A extended spectrum beta-lactamases (ESBLs), class C cephalosporinases, and class A and D carbapenemases (KPC and OXA-48, respectively) as well as multidrug-resistant (MDR) Enterobacterales.[4] Ceftibuten-ledaborbactam etzadroxil has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the US Food and Drug Administration (FDA) for cUTI and uncomplicated urinary tract infections. Ceftibuten-ledaborbactam etzadroxil is an investigational drug and is not yet approved in any country for commercial use. About complicated urinary tract infections (cUTI) Complicated UTIs, which include pyelonephritis (kidney infections), are defined as urinary tract infections ascending from the bladder accompanied by local and systemic signs and symptoms and are one of the most common bacterial infections in hospital and community settings. Increasing resistance of bacteria causing complicated urinary tract infections has led to limited availability of effective oral antibiotic treatment options.[1] Currently, there are no approved oral beta-lactam or beta-lactam/beta-lactamase inhibitor combinations that are effective against Enterobacterales expressing Ambler class A ESBLs, class C cephalosporinases, and class A & D serine carbapenemases (KPC and OXA-48). About Venatorx Pharmaceuticals, Inc. Venatorx is a private, late-stage clinical pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and hard-to-treat viral infections. Venatorx also developed cefepime-taniborbactam, an intravenous-only antibiotic that successfully completed a Phase 3 study in adults with complicated urinary tract infections (cUTI), including pyelonephritis. The ceftibuten-ledaborbactam etzadroxil project has been funded in whole or in part with Federal funds from National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201600029C and the Department of Health and Human Services; Office of the Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50123C00050. For more information about Venatorx and its anti-infectives portfolio, please visit About Basilea Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit Disclaimer This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For further information, please contact: Peer Nils Schröder, PhDHead of Corporate Communications & Investor RelationsBasilea Pharmaceutica International Ltd, Allschwil Hegenheimermattweg 167b4123 AllschwilSwitzerland Phone +41 61 606 1102 E-mail media_relations@ This ad hoc announcement can be downloaded from References T. P. Lodise, T. Chopra, B. H. Nathanson et al. Epidemiology of Complicated Urinary Tract Infections due to Enterobacterales Among Adult Patients Presenting in Emergency Departments Across the United States. Open Forum Infectious Diseases 2022, Jun 24;9(7):ofac315. M. D. Zilberberg, B. H. Nathanson, K. Sulham et al. Descriptive Epidemiology and Outcomes of Hospitalizations With Complicated Urinary Tract Infections in the United States, 2018. Open Forum Infectious Diseases 2022, Jan 10;9(1):ofab591 C. F. de Oliveira, M. B. Dorr, K. Lowe et al. Evaluation of Single and Multiple Dose Safety and Pharmacokinetics of Ledaborbactam Etzadroxil and Ceftibuten-Ledaborbactam Etzadroxil in Healthy Volunteers. Open Forum Infectious Diseases 2025, Jan 29;12(Suppl 1):ofae631.1425 J. A. Karlowsky, M. G. Wise, M. A. Hackel et al. Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-β-Lactamase-Positive Clinical Isolates of Enterobacterales from a 2018–2020 Global Surveillance Collection. Antimicrobial Agents and Chemotherapy 2022, Nov 15;66(11):e0093422 Attachment Press release (PDF)Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
Santhera Secures Agreement with GEN for the Distribution of AGAMREE® (Vamorolone) in Türkiye
Pratteln, Switzerland, 13 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN) for the distribution and promotion of AGAMREE® (vamorolone) in Türkiye for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older. Supply and sales by GEN are expected to start in the first half of 2026, initially on a named patient basis, followed by commercial sales. Santhera has received a small upfront payment and, as per previous agreements, will receive an ongoing percentage of net sales. Dario Eklund, Chief Executive Officer of Santhera, said: 'As leaders in the Turkish specialty pharmaceuticals market, GEN were a natural choice for Santhera as we looked for a high-quality distribution partner. We look forward to working closely in the run up to launching in the country in 2026, to provide access to the many DMD patients lacking suitable treatment options.' Abidin Gülmüş, Chairman/CEO of GEN, added: 'The potential for AGAMREE is clear, and we are determined to ensure this DMD therapy reaches patients in Türkiye without delay. We understand the rare disease market deeply, use our longtime experience on neuromuscular diseases and look forward to partnering with Santhera in the months and years ahead.' About AGAMREE® (vamorolone) AGAMREE is a novel drug with a mode of action based on binding to the same receptor as glucocorticoids but modifying its downstream activity. Moreover, it is not a substrate for the 11-β-hydroxysteroid dehydrogenase (11β-HSD) enzymes that may be responsible for local drug amplification and corticosteroid-associated toxicity in local tissues [1-4]. This mechanism has shown the potential to 'dissociate' efficacy from steroid safety concerns and therefore AGAMREE is positioned as a dissociative anti-inflammatory drug and an alternative to existing corticosteroids, the current standard of care in children and adolescent patients with DMD [1-4]. In the pivotal VISION-DMD study, AGAMREE met the primary endpoint Time to Stand (TTSTAND) velocity versus placebo (p=0.002) at 24 weeks of treatment and showed a good safety and tolerability profile [1, 4]. The most commonly reported side effects were cushingoid features, vomiting, weight increase and irritability. Side effects were generally of mild to moderate severity. Currently available data show that AGAMREE, unlike corticosteroids, has no restriction of growth [5] and no negative effects on bone metabolism as demonstrated by normal bone formation and bone resorption serum markers [6]. ▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. References:[1] Dang UJ et al. (2024) Neurology 2024;102:e208112. Link.[2] Guglieri M et al (2022). JAMA Neurol. 2022;79(10):1005-1014. doi:10.1001/jamaneurol.2022.2480. Link. [3] Liu X et al (2020). Proc Natl Acad Sci USA 117:24285-24293[4] Heier CR et al (2019). Life Science Alliance DOI: 10.26508[5] Ward et al., WMS 2022, FP.27 - Poster 71. Link.[6] Hasham et al., MDA 2022 Poster presentation. Link. About SantheraSanthera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular diseases with high unmet medical need. The Company has an exclusive license from ReveraGen for all indications worldwide to AGAMREE® (vamorolone), a dissociative steroid with novel mode of action, which was investigated in a pivotal study in patients with Duchenne muscular dystrophy (DMD) as an alternative to standard corticosteroids. AGAMREE for the treatment of DMD is approved in the U.S. by the Food and Drug Administration (FDA), in the EU by the European Medicines Agency (EMA), in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA), in China by the National Medical Products Administration (NMPA) and Hong Kong by the Department of Health (DoH). Santhera has out-licensed rights to AGAMREE for North America to Catalyst Pharmaceuticals and for China and certain countries in Southeast Asia to Sperogenix Therapeutics. For further information, please visit AGAMREE® is a trademark of Santhera Pharmaceuticals. About GENGen İlaç ve Sağlık Ürünleri San. Ve Tic. A.Ş. (BIST: is Türkiye's leading specialty pharmaceutical company, focused on developing innovative therapies across multiple therapeutic areas including neurological and neuromuscular disorders (DMD, SMA, etc) since 1998. GEN manufactures high-quality, competitive products at its GMP-certified facility and pursues original drug development through two dedicated R&D centers and investments. For further information, please visit For further information please contact: SantheraCatherine Isted, Chief Financial Officer: IR@ ICR Healthcare Santhera@ GEN Deniz Karagulle, Chief Commercial Officer Bulutay Gunes, Sr. Head of Corporate Brand Ali Ketencioglu, Investor Relations Manager Disclaimer / Forward-looking statements This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements. # # # Attachment 250813 - Santhera Gen Ilac Turkey Distribution Agreement
Forbes
2 days ago
- Forbes
Beyond Benefits: Building A Brain-Smart Company In An AI-Powered World
Kelly O'Brien leads the Business Collaborative for Brain Health at UsAgainstAlzheimer's, advancing brain health in workplaces and policy. As AI, automation and hybrid work reshape the workplace, the premium on brain skills—focus, creativity, critical thinking—has never been higher. Yet just as cognitive demands intensify, brain-based conditions like depression, anxiety, migraines, ADHD and early cognitive decline are driving up costs and eroding productivity and innovation. I believe leaders that pay attention to the operating system that inspires AI—the human brain—will have a competitive edge. Here's how: Take a systems-level approach to wellness. The good news is that employers are no longer limited to check-the-box wellness programs. Today's leaders have access to data, neuroscience and AI-powered tools that can make brain health and brain skills both measurable and actionable. CEOs who embrace a systems-level approach to build brain capital—linking health, learning, work design and purpose—won't just help mitigate risk; they can build more resilient, adaptive and high-performing organizations. Over the decades, "wellbeing" programs have expanded—from a focus on safety to wellness to mental health and now to whole health. Today, it's time for these efforts to evolve beyond human resources programs and become a strategic, organization-wide priority. Initiatives that lack strategic alignment, clinical integration or meaningful measurement rarely move the needle. Instead, let's seek to reshape employer-sponsored care by putting brain health at the center of our strategy. Use data to promote resilience and early intervention. Emerging value-based primary care platforms are increasingly equipped to embed cognitive and emotional screening into routine workflows, enabling earlier identification of risk during voluntary, patient-driven encounters. Digital assessment tools like Neurotrack and Linus Health are making cognitive health more visible and actionable—when individuals opt in—while protecting privacy. Analytics platforms such as Merative can unify de-identified claims, well-being and productivity data to detect system-level trends and inform population health strategies. Diagnostic and treatment innovations—including emerging blood-based biomarkers, neurotech solutions and AI driven risk scores—may also bring prevention within reach. Meanwhile, pilot programs involving Blue Ash Ventures' Brain Health Matrix and the Center for Brain Health's Brain Health Index are actively working to build the business case for brain resilience and skill-building strategies. Tools like the HERO Health and Well-being Best Practices Scorecard, developed in collaboration with Mercer, also provide strategic guidance for employers aiming to drive measurable impact. Integrate your findings to maximize impact. What once lived in a silo can now live in a system. Employers can embed brain health into benefits design, offer targeted support to high-risk populations like caregivers and employees with comorbidities and create cognitively supportive environments—think protected focus time, reduced meeting overload and better collaboration. They can build 'brain capital dashboards' that map cognitive strengths across roles and use adaptive learning platforms to develop brain-based skills like attention, creativity and agility. This is not about perks—it's about performance. Data backs this up. Targeted programs for at-risk groups can often yield two to three times the initial investment in savings. Culture-driven initiatives, like psychological safety and leadership modeling, often outperform transactional efforts. Employers embedding collaborative care‑style services that combine fast access, measurement-based care, referrals, coaching and outreach consistently lead to better clinical outcomes, reduced medical costs and improved employee engagement. The shift toward Wellbeing 5.0 is already underway. It puts brain health at the core, leverages AI for personalized precision, integrates support into the rhythm of work and uses data for prevention. It aligns human performance with purpose, belonging and inclusion, which is especially critical as we navigate the hybrid era and workforce transformation. In this model, wellbeing isn't a sideline—it's a strategy. Investing in brain health isn't just about doing the right thing, or simply a recruitment and retention strategy. It's about protecting and unlocking your most valuable competitive advantage: human intelligence. In a world increasingly defined by machines, it's the quality of human cognition—our capacity to learn, adapt, create and lead—that will determine which organizations thrive. CEOs who understand this, and act on it, won't just build brain-smart companies. They'll build future-ready ones. Forbes Business Council is the foremost growth and networking organization for business owners and leaders. Do I qualify?
